• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Isofol Medical

0,71 SEK

+5,03 %

Mindre end 1K følgere

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+5,03 %
-2,34 %
+12,70 %
-2,61 %
+1,43 %
-27,59 %
+48,80 %
-91,07 %
-94,73 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, one of the world's most common cancers, where the medical need for better treatments is great.

Læs mere
Markedsværdi
227,55 mio. SEK
Aktieomsætning
169,31 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
EPS og udbytte
Finanskalender
Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
25.8
2026

Delårsrapport Q2'26

12.11
2026

Delårsrapport Q3'26

12.2
2027

Årsrapport '26

Selskabsmeddelelse19.5.2026, 14.45

Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026

Isofol Medical
Pressemeddelelse19.5.2026, 11.14

Redeye: Isofol Medical (Q1 Review): Tailwind despite slower recruitment

Isofol Medical
Eksterne analyser19.5.2026, 07.38

Isofol Medical: Taking action on recruitment - ABG

* Solid cost control * Slower-than-expected patient recruitment * Negative share price reaction expected Solid cost control Net income came in fairly in line with expectations at SEK -15m (vs. ABGSCe at SEX -14m and SEK -13m in Q4'25), with CF from operating...

Isofol Medical

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse19.5.2026, 06.00

Isofol Medical AB (publ) publishes interim report, January – March 2026

Isofol Medical
Selskabsmeddelelse30.4.2026, 06.00

New number of shares and votes in Isofol

Isofol Medical
Selskabsmeddelelse15.4.2026, 14.00

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Isofol Medical
Pressemeddelelse15.4.2026, 07.10

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Isofol Medical
Selskabsmeddelelse10.4.2026, 06.00

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Isofol Medical
Selskabsmeddelelse31.3.2026, 15.00

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Isofol Medical
Selskabsmeddelelse18.3.2026, 12.50

Isofol secures license rights for arfolitixorin in autism

Isofol Medical
Selskabsmeddelelse13.3.2026, 17.40

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Isofol Medical
Selskabsmeddelelse11.3.2026, 14.30

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Isofol Medical
Selskabsmeddelelse9.3.2026, 10.00

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Isofol Medical
Pressemeddelelse3.3.2026, 07.30

Isofol presents at investor meetings in March

Isofol Medical
Eksterne analyser25.2.2026, 06.22

Isofol Medical: From first lessons to second execution - ABG

* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.1-10.5/share Strong early efficacy signal Isofol today announced that all six currently evaluable RAS-mutated metastatic colorectal cancer patients in Part 1 of its Phase...

Isofol Medical
Selskabsmeddelelse24.2.2026, 08.32

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Isofol Medical
Pressemeddelelse19.2.2026, 08.36

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Isofol Medical
Selskabsmeddelelse18.2.2026, 06.30

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Isofol Medical
Eksterne analyser15.1.2026, 12.46

Isofol Medical: Learn from the first, deliver on the second - ABG

* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0.1-10.5/share Huge unmet medical needIsofol is developing arfolitixorin, a next-generation active folate designed to enhance standard chemotherapy built...

Isofol Medical
Pressemeddelelse9.1.2026, 06.30

Isofol participates in the ASCO GI congress

Isofol Medical